These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20876669)

  • 1. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial.
    Agarwal R; Leehey DJ; Olsen SM; Dahl NV
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):114-21. PubMed ID: 20876669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.
    Agarwal R; Rizkala AR; Kaskas MO; Minasian R; Trout JR
    Kidney Int; 2007 Sep; 72(5):638-42. PubMed ID: 17622274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
    Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
    Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.
    Jaber BL
    Kidney Int; 2008 Feb; 73(4):511-2; author 512. PubMed ID: 18235527
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
    Nguyen TV
    Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron sucrose or ferric gluconate?
    Duffy CI
    Am J Kidney Dis; 2001 Dec; 38(6):1442. PubMed ID: 11728988
    [No Abstract]   [Full Text] [Related]  

  • 11. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
    Stancu S; Bârsan L; Stanciu A; Mircescu G
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
    Liu D; Wang LN; Li HX; Huang P; Qu LB; Chen FY
    J Int Med Res; 2017 Apr; 45(2):383-398. PubMed ID: 28415944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.
    Winkelmayer WC; Goldstein BA; Mitani AA; Ding VY; Airy M; Mandayam S; Chang TI; Brookhart MA; Fishbane S
    Am J Kidney Dis; 2017 Jun; 69(6):771-779. PubMed ID: 28063734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of intravenous iron sucrose use in the elderly patient.
    Reed J; Charytan C; Yee J
    Consult Pharm; 2007 Mar; 22(3):230-8. PubMed ID: 17658969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
    Lyseng-Williamson KA; Keating GM
    Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral iron therapy: a single institution's experience over a 5-year period.
    Laman CA; Silverstein SB; Rodgers GM
    J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients.
    Sirken G; Raja R; Rizkala AR
    Clin Nephrol; 2006 Nov; 66(5):348-56. PubMed ID: 17140164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.